2023
DOI: 10.33371/ijoc.v17i4.995
|View full text |Cite
|
Sign up to set email alerts
|

Survival of Lung Adenocarcinoma Patients with Tyrosine Kinase Inhibitor Therapy Based on EGFR Mutation Status in Tumor and Plasma Samples

Haryati Haryati,
Fidya Rahmadhany Arganita,
Ika Kustiyah Oktaviyanti

Abstract: Background:The prognosis for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is greatly improved when treated with tyrosine kinase inhibitor (TKI). In this context, EGFR mutation status should be determined at the diagnosis stage but circulating tumor DNA (ctDNA) has been increasingly used for molecular profiling. Therefore, this study aimed to establish the correlation between the presence of ctDNA before TKI therapy and subsequent clinical outcomes Methods: A total of 18 pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 22 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?